<26 and 26 weeks of gestation. Univariable and multivariable analysis were used to compare the rates of IVH and mortality between the two groups. RESULTS: There was no significant difference in the rate of IVH (vaginal vs. cesarean; 15.2 vs. 9.4%, P¼0.275). Also, there was no difference in the rate of IVH in the neonates born <26 and 26 weeks of gestation (22.0 vs. 14.0%, P¼0.200, 9.1 vs. 6.5%, P¼0.724), respectively. Meanwhile, neonatal mortality rate was significantly lower in the cesarean delivery group (29.5% vs. 18 OBJECTIVE: Maternal antenatal corticosteroid therapy (MACT) significantly reduces RDS, IVH, neonatal death, and NEC in neonates born before 32 weeks and appears to reduce respiratory morbidity in late preterm neonates if administered very close to delivery. It is not clear if MACT just before 34 weeks is beneficial if birth occurs LP/ET. Our objective was to compare short-term outcomes of LP/ET (34 0/7 and 37 6/7 weeks) neonates that were exposed to MACT between 30 0/7 to 33 6/7 weeks gestation versus those unexposed. STUDY DESIGN: This is a retrospective cohort study of neonates born between at Stony Brook University Hospital from January 1, 2013 to December 31, 2014. The New York State Perinatal Database System (NYSPDS) and inpatient records were used to categorize neonates according to MACT exposure between 30 0/7 and 33 6/7 weeks versus MACT non-exposure (no MACT exposure at all or exposure only before 30 weeks gestation). Primary respiratory outcomes were: requirement for delivery room resuscitation, RDS, TTN, air leak syndrome or surfactant administration. Primary metabolic outcomes were: jaundice requiring phototherapy, feeding difficulties and hypoglycemia. Severity of respiratory illness was defined using a composite Score for Neonatal Acute Physiology Perinatal Extension II (SNAPPE II score). Multiple logistic regression models were employed to examine whether ACT exposure (versus non-exposure) was significantly associated with the probability of neonatal respiratory and metabolic comorbidity. RESULTS: Five hundred fifty five infants born LP/ET were identified, of which 65 (13%) were exposed to ACT between 30 0/7 and 33 6/7 weeks. Both groups had similar respiratory outcomes. MACT neonates were more likely to receive TPN or intravenous fluids for at least two days or hypoglycemia. Logistics regression analysis showed a nonsignificant trend toward MACT neonates experiencing more metabolic morbidity. OBJECTIVE: To systematically review the literature and quantitatively compare the efficacy and adverse perinatal outcomes of cervical pessary, cervical cerclage, vaginal progesterone, and injectable progesterone (17-OHPC) for the prevention of preterm birth (PTB) <35 weeks in women with twin gestations and a sonographic short cervix. STUDY DESIGN: A computerized database search (MEDLINE, PubMed, EMBASE, Cochrane CENTRAL) was conducted to identify randomized controlled trials of patients treated with cervical cerclage, cervical pessary, vaginal progesterone, or 17-OHPC published from January 1966 through July 2018. Data were also obtained from published systematic reviews with individual patient data (IPD) meta-analyses. We used a user-written package in Stata (Stata Corp, College Station, TX) to perform multivariate random-effects metaanalysis and meta-regression on a dataset of point estimates, variances, and covariances. Frequentist method was employed to calculate ranking probabilities. RESULTS: Sixteen studies with 1,019 women allocated to four different treatment arms were included for analysis. Traditional pairwise meta-analysis showed that compared with placebo, vaginal progesterone decreased PTB <35 weeks (RR 0.74, 95% CI 0.56, 0.96). Cervical pessary, 17-OHPC, and cervical cerclage did not significantly reduce PTB risk. Cerclage placement increased risk (RR 2.19 (95% CI 0.72, 6.63). Multi-treatment comparisons found that when compared, vaginal progesterone significantly decreased risk of preterm birth <35 weeks when compared with cerclage (OR 0.14; 95% CI 0.03, 0.68) and 17-OHPC (OR 0.35; 95% CI 0.12, 1.02). Cumulative ranking probability indicated a 66% probability that vaginal progesterone was the best treatment for preventing preterm birth while cervical cerclage had an 85% probability of being the worst treatment. Due to a lack of uniformity in the reporting of other perinatal outcomes and the lack of power for these uncommon events, reliable estimates could not be calculated. CONCLUSION: When compared with other agents, vaginal progesterone appears to be the most effective in lowering the risk of preterm birth in twin gestations with a sonographic short cervix while placement of a cervical cerclage appears to elevate this risk.
OBJECTIVE: Maternal antenatal corticosteroid therapy (MACT) significantly reduces RDS, IVH, neonatal death, and NEC in neonates born before 32 weeks and appears to reduce respiratory morbidity in late preterm neonates if administered very close to delivery. It is not clear if MACT just before 34 weeks is beneficial if birth occurs LP/ET. Our objective was to compare short-term outcomes of LP/ET (34 0/7 and 37 6/7 weeks) neonates that were exposed to MACT between 30 0/7 to 33 6/7 weeks gestation versus those unexposed. STUDY DESIGN: This is a retrospective cohort study of neonates born between at Stony Brook University Hospital from January 1, 2013 to December 31, 2014. The New York State Perinatal Database System (NYSPDS) and inpatient records were used to categorize neonates according to MACT exposure between 30 0/7 and 33 6/7 weeks versus MACT non-exposure (no MACT exposure at all or exposure only before 30 weeks gestation). Primary respiratory outcomes were: requirement for delivery room resuscitation, RDS, TTN, air leak syndrome or surfactant administration. Primary metabolic outcomes were: jaundice requiring phototherapy, feeding difficulties and hypoglycemia. Severity of respiratory illness was defined using a composite Score for Neonatal Acute Physiology Perinatal Extension II (SNAPPE II score). Multiple logistic regression models were employed to examine whether ACT exposure (versus non-exposure) was significantly associated with the probability of neonatal respiratory and metabolic comorbidity. RESULTS: Five hundred fifty five infants born LP/ET were identified, of which 65 (13%) were exposed to ACT between 30 0/7 and 33 6/7 weeks. Both groups had similar respiratory outcomes. MACT neonates were more likely to receive TPN or intravenous fluids for at least two days or hypoglycemia. Logistics regression analysis showed a nonsignificant trend toward MACT neonates experiencing more metabolic morbidity. CONCLUSION: MACT between 30-34 weeks did not appear to provide significant benefit if neonates delivered between 34-37 weeks. MACT between 30-34 weeks may not preclude retreatment if delivery between 34-37 weeks appears likely.
552 Twin pregnancies with short cervix: Vaginal progesterone is agent of choice for preterm delivery prevention OBJECTIVE: To systematically review the literature and quantitatively compare the efficacy and adverse perinatal outcomes of cervical pessary, cervical cerclage, vaginal progesterone, and injectable progesterone (17-OHPC) for the prevention of preterm birth (PTB) <35 weeks in women with twin gestations and a sonographic short cervix. STUDY DESIGN: A computerized database search (MEDLINE, PubMed, EMBASE, Cochrane CENTRAL) was conducted to identify randomized controlled trials of patients treated with cervical cerclage, cervical pessary, vaginal progesterone, or 17-OHPC published from January 1966 through July 2018. Data were also obtained from published systematic reviews with individual patient data (IPD) meta-analyses. We used a user-written package in Stata (Stata Corp, College Station, TX) to perform multivariate random-effects metaanalysis and meta-regression on a dataset of point estimates, variances, and covariances. Frequentist method was employed to calculate ranking probabilities. RESULTS: Sixteen studies with 1,019 women allocated to four different treatment arms were included for analysis. Traditional pairwise meta-analysis showed that compared with placebo, vaginal progesterone decreased PTB <35 weeks (RR 0.74, 95% CI 0.56, 0.96). Cervical pessary, 17-OHPC, and cervical cerclage did not significantly reduce PTB risk. Cerclage placement increased risk (RR 2.19 (95% CI 0.72, 6.63). Multi-treatment comparisons found that when compared, vaginal progesterone significantly decreased risk of preterm birth <35 weeks when compared with cerclage (OR 0.14; 95% CI 0.03, 0.68) and 17-OHPC (OR 0.35; 95% CI 0.12, 1.02). Cumulative ranking probability indicated a 66% probability that vaginal progesterone was the best treatment for preventing preterm birth while cervical cerclage had an 85% probability of being the worst treatment. Due to a lack of uniformity in the reporting of other perinatal outcomes and the lack of power for these uncommon events, reliable estimates could not be calculated. CONCLUSION: When compared with other agents, vaginal progesterone appears to be the most effective in lowering the risk of preterm birth in twin gestations with a sonographic short cervix while placement of a cervical cerclage appears to elevate this risk.
Poster Session III OBJECTIVE: We sought to evaluate whether the most common clinical conditions leading to recurrent SPTB were associated with differences in delivery gestational age (GA). STUDY DESIGN: This is a secondary analysis of four prospective, multicenter studies that enrolled women at high risk for SPTB 15-36 weeks; study #1¼observational, studies #2 & #3 ¼ RCTs with negative findings (intervention did not impact SPTB rate or neonatal outcomes); study #4 ¼ RCT of MgSO4 vs. placebo showing reduction in cerebral palsy at age 2 with MgSO4 treatment. We included women with singleton, non-anomalous pregnancies with 1 prior SPTB <37 weeks who had a recurrent PTB <37 weeks. Each woman was assessed for the presence of 1 possible underlying recurrent SPTB etiologies using uniform definitions and clinical data available antenatally: (a) intra-amniotic infection, (b) placental abruption, (c) pre-eclampsia / IUGR, and (d) PPROM (Table 1) . Maternal characteristics and delivery GA were compared for each phenotype. Data were analyzed with chi-square, t-test, Cox regression, and KaplanMeier survival analyses. RESULTS: 1,205 women met inclusion criteria; the mean delivery GA was 31.4 +/-4.1 weeks. 531 (44%) had 1 phenotype and 185 (15%) had 2 phenotypes. The most common phenotype was PPROM, followed by intra-amniotic infection and placental abruption. Women with each of these phenotypes delivered earlier than those without each phenotype (Table 1) . Black women were more likely to have PPROM (53.5% vs. 46.5%, p¼0.003) compared to women of other races. Overall, 37% used 17P; women who received 17P delivered later than those who did not receive 17P (32.8 vs. 30.5 weeks), p<0.001. In Cox regression models adjusted for black race, 17P, and smoking, intra-amniotic infection (Hazard Ratio 2.34, 95% CI 1.49-3.66), placental abruption (Hazard Ratio 1.78, 95% CI 1.21-2.59), and PPROM (Hazard Ratio 1.40, 95% CI 1.15-1.72) were associated with an earlier delivery GA, whereas pre-eclampsia/IUGR was associated with a later delivery GA (Hazard Ratio 0.76, 95% CI 0.60-0.97). In Kaplan-Meier survival analyses adjusting for black race, 17P, and smoking, each additional phenotype was associated with earlier GA at delivery, log-rank p<0.001 (Figure 1) . CONCLUSION: Women with a history of SPTB who subsequently have a recurrent SPTB and are clinically identified to have evidence of intra-amniotic infection, abruption, or PPROM deliver earlier than those without each of these phenotypes.
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